Clinical Trials Logo

Opsoclonus-myoclonus Syndrome clinical trials

View clinical trials related to Opsoclonus-myoclonus Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00806182 Completed - Clinical trials for Opsoclonus-myoclonus Syndrome

Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome

OMS
Start date: January 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine if cytokines, inflammatory mediators, are increased in spinal fluid and blood, correlate with disease activity, and could serve as biomarkers or therapeutic targets in children with opsoclonus-myoclonus syndrome (OMS), an autoimmune complication of the tumor neuroblastoma.

NCT ID: NCT00244361 Completed - Ataxia Clinical Trials

Effectiveness of Rituximab in Pediatric OMS Patients.

Start date: June 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to reduce the symptoms of OMS by testing rituximab (Rituxan®), to remove B lymphocytes that make antibodies and trigger brain inflammation. Evidence suggests that autoimmune brain inflammation causes the symptoms of OMS. This study of blood and spinal fluid intends to find out what effect rituximab has on OMS and on the spinal fluid B-cells. Rituximab targets and destroys B-cells, which make antibodies that can attack the brain and cause may OMS. It is infused through a vein over a period of several hours. Rituximab has been used widely and studied extensively since its approval in 1997 by the U.S. Food and Drug Administration (FDA) for non-Hodgkin's B-cell Lymphoma (NHL). Today, more than 300,000 patients have received rituximab, and it is part of more than 200 completed, ongoing, or planned clinical trials. Rituximab is not FDA-approved for OMS.